The diabetic gastroparesis treatment market size has grown strongly in recent years. It will grow from $3.68 billion in 2023 to $3.86 billion in 2024 at a compound annual growth rate (CAGR) of 5.0%. The growth observed in the historical period can be attributed to factors such as the increasing prevalence of diabetes, limited treatment options, a rise in awareness and diagnosis of diabetic gastroparesis, and the development of healthcare infrastructure.
The diabetic gastroparesis treatment market size is expected to see strong growth in the next few years. It will grow to $4.73 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period can be attributed to the adoption of precision medicine and personalized therapies, the growing diabetic population, increased research and development efforts, and a shift in the regulatory landscape. Noteworthy trends expected in the forecast period include technological innovations in treatments, the emergence of novel therapies, a focus on symptom management, the utilization of telemedicine and remote monitoring, and interventions targeting the gut microbiome.
The diabetic gastroparesis treatment market is poised for growth, driven by the increasing prevalence of diabetes. The prevalence of diabetes, indicating the percentage of the population diagnosed with diabetes at a specific time, has led to a growing demand for diabetic gastroparesis treatment. This treatment is crucial for managing symptoms and complications associated with gastroparesis, a common complication of diabetes. For example, as of April 2023, The British Diabetic Association reported that 4.3 million individuals in the UK are living with diabetes, with more than 2.4 million at high risk of type 2 diabetes. The registration numbers for 2021–22 reached 148,951, emphasizing the significant impact of diabetes prevalence on the diabetic gastroparesis treatment market.
The growth of the diabetic gastroparesis treatment market is further fueled by the increase in the prediabetic population. Prediabetic individuals, with elevated blood sugar levels not yet meeting the diabetes diagnosis criteria, represent a substantial portion of the population. The emphasis on effective prevention and treatment strategies for diabetes and its complications, including gastroparesis, is evident. For instance, data from the Centers for Disease Control and Prevention in June 2022 revealed that 96 million people aged 18 or older have prediabetes in the United States, constituting 38.0% of the adult population. The significant prediabetic population is a key driver for the growth of the diabetic gastroparesis treatment market.
The diabetic gastroparesis treatment market is anticipated to experience growth due to the rising number of surgical procedures. Surgical interventions in diabetic patients, such as Nissen fundoplication, gastric bypass surgery, and cholecystectomy, can lead to post-surgical gastroparesis. The increase in surgical procedures, as reported by the Aesthetic Society in April 2022, with a 54% rise in surgical aesthetic procedures in 2021 compared to 2020, contributes to the demand for diabetic gastroparesis treatment.
A notable trend in the diabetic gastroparesis treatment market is the development of new medications. Major companies are actively engaged in creating innovative products to maintain their market positions. In June 2023, the U.S. Food and Drug Administration approved two medications, Empagliflozin (Jardiance) and Synjardy (Empagliflozin and Metformin Hydrochloride), for treating type 2 diabetes in children aged ten and older. This approval marks a significant advancement in diabetes treatment, offering more comprehensive blood sugar management.
Strategic alliances are a key focus for major companies in the diabetic gastroparesis treatment market to enhance their market positions. For instance, in August 2021, Fitbit, a U.S.-based consumer electronics company, entered into an agreement with LifeScan, a U.S.-based diagnostic systems manufacturer in the diabetes market. This alliance aimed to link health tracking apps with glucose monitoring devices, providing diabetes patients access to the OneTouch Reveal app. The integration allows users to sync OneTouch blood glucose data with metrics collected by Fitbit, offering a holistic approach to diabetes management.
Major companies operating in the diabetic gastroparesis treatment market report are Cardinal Health Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, GlaxoSmithKline plc, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kimberly-Clark Corporation, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Allergan Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC.
North America was the largest region in the diabetic gastroparesis treatment market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic gastroparesis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary treatments for diabetic gastroparesis include medication and surgery. Medications, such as gastroprokinetic agents, antiemetic agents, and botulinum toxin, are utilized for the diagnosis, treatment, prevention, or alleviation of symptoms associated with this medical condition. These medications are administered orally or via injections and are distributed through hospital pharmacies, retail pharmacies, and other channels catering to hospitals, homecare, specialty clinics, and similar healthcare settings.
The diabetic gastroparesis treatment market research report is one of a series of new reports that provides diabetic gastroparesis treatment market statistics, including diabetic gastroparesis treatment industry global market size, regional shares, competitors with a diabetic gastroparesis treatment market share, detailed diabetic gastroparesis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetic gastroparesis treatment industry. This diabetic gastroparesis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The diabetic gastroparesis treatment market consists of revenues earned by entities by providing services such as medical evaluation, medication management, dietary consultation, insulin adjustment, lifestyle modifications, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic gastroparesis treatment market also includes sales of metoclopramide, erythromycin, domperidone, promethazine, and ondansetron (Zofran). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The diabetic gastroparesis treatment market size is expected to see strong growth in the next few years. It will grow to $4.73 billion in 2028 at a compound annual growth rate (CAGR) of 5.2%. The anticipated growth in the forecast period can be attributed to the adoption of precision medicine and personalized therapies, the growing diabetic population, increased research and development efforts, and a shift in the regulatory landscape. Noteworthy trends expected in the forecast period include technological innovations in treatments, the emergence of novel therapies, a focus on symptom management, the utilization of telemedicine and remote monitoring, and interventions targeting the gut microbiome.
The diabetic gastroparesis treatment market is poised for growth, driven by the increasing prevalence of diabetes. The prevalence of diabetes, indicating the percentage of the population diagnosed with diabetes at a specific time, has led to a growing demand for diabetic gastroparesis treatment. This treatment is crucial for managing symptoms and complications associated with gastroparesis, a common complication of diabetes. For example, as of April 2023, The British Diabetic Association reported that 4.3 million individuals in the UK are living with diabetes, with more than 2.4 million at high risk of type 2 diabetes. The registration numbers for 2021–22 reached 148,951, emphasizing the significant impact of diabetes prevalence on the diabetic gastroparesis treatment market.
The growth of the diabetic gastroparesis treatment market is further fueled by the increase in the prediabetic population. Prediabetic individuals, with elevated blood sugar levels not yet meeting the diabetes diagnosis criteria, represent a substantial portion of the population. The emphasis on effective prevention and treatment strategies for diabetes and its complications, including gastroparesis, is evident. For instance, data from the Centers for Disease Control and Prevention in June 2022 revealed that 96 million people aged 18 or older have prediabetes in the United States, constituting 38.0% of the adult population. The significant prediabetic population is a key driver for the growth of the diabetic gastroparesis treatment market.
The diabetic gastroparesis treatment market is anticipated to experience growth due to the rising number of surgical procedures. Surgical interventions in diabetic patients, such as Nissen fundoplication, gastric bypass surgery, and cholecystectomy, can lead to post-surgical gastroparesis. The increase in surgical procedures, as reported by the Aesthetic Society in April 2022, with a 54% rise in surgical aesthetic procedures in 2021 compared to 2020, contributes to the demand for diabetic gastroparesis treatment.
A notable trend in the diabetic gastroparesis treatment market is the development of new medications. Major companies are actively engaged in creating innovative products to maintain their market positions. In June 2023, the U.S. Food and Drug Administration approved two medications, Empagliflozin (Jardiance) and Synjardy (Empagliflozin and Metformin Hydrochloride), for treating type 2 diabetes in children aged ten and older. This approval marks a significant advancement in diabetes treatment, offering more comprehensive blood sugar management.
Strategic alliances are a key focus for major companies in the diabetic gastroparesis treatment market to enhance their market positions. For instance, in August 2021, Fitbit, a U.S.-based consumer electronics company, entered into an agreement with LifeScan, a U.S.-based diagnostic systems manufacturer in the diabetes market. This alliance aimed to link health tracking apps with glucose monitoring devices, providing diabetes patients access to the OneTouch Reveal app. The integration allows users to sync OneTouch blood glucose data with metrics collected by Fitbit, offering a holistic approach to diabetes management.
Major companies operating in the diabetic gastroparesis treatment market report are Cardinal Health Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Ipca Laboratories Ltd., Abbott Laboratories, GlaxoSmithKline plc, AstraZeneca plc, Medtronics plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Kimberly-Clark Corporation, Teva Pharmaceutical Industries Ltd., Janssen Global Services LLC, Boston Scientific Corporation, Fresenius Kabi AG, Bausch Health Companies Inc., Allergan Inc., Salix Pharmaceuticals Inc., Ironwood Pharmaceuticals Inc., Wockhardt Ltd., ANI Pharmaceuticals Inc., Endologic LLC, Vanda Pharmaceuticals Inc., Rhythm Pharmaceuticals Inc., Theravance Biopharma Inc., Neurogastrx Inc., Evoke Pharma Inc., CinRx Pharma LLC.
North America was the largest region in the diabetic gastroparesis treatment market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the diabetic gastroparesis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diabetic gastroparesis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The primary treatments for diabetic gastroparesis include medication and surgery. Medications, such as gastroprokinetic agents, antiemetic agents, and botulinum toxin, are utilized for the diagnosis, treatment, prevention, or alleviation of symptoms associated with this medical condition. These medications are administered orally or via injections and are distributed through hospital pharmacies, retail pharmacies, and other channels catering to hospitals, homecare, specialty clinics, and similar healthcare settings.
The diabetic gastroparesis treatment market research report is one of a series of new reports that provides diabetic gastroparesis treatment market statistics, including diabetic gastroparesis treatment industry global market size, regional shares, competitors with a diabetic gastroparesis treatment market share, detailed diabetic gastroparesis treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the diabetic gastroparesis treatment industry. This diabetic gastroparesis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The diabetic gastroparesis treatment market consists of revenues earned by entities by providing services such as medical evaluation, medication management, dietary consultation, insulin adjustment, lifestyle modifications, and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The diabetic gastroparesis treatment market also includes sales of metoclopramide, erythromycin, domperidone, promethazine, and ondansetron (Zofran). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Diabetic Gastroparesis Treatment Market Characteristics3. Diabetic Gastroparesis Treatment Market Trends and Strategies32. Global Diabetic Gastroparesis Treatment Market Competitive Benchmarking33. Global Diabetic Gastroparesis Treatment Market Competitive Dashboard34. Key Mergers and Acquisitions in the Diabetic Gastroparesis Treatment Market
4. Diabetic Gastroparesis Treatment Market - Macro Economic Scenario
5. Global Diabetic Gastroparesis Treatment Market Size and Growth
6. Diabetic Gastroparesis Treatment Market Segmentation
7. Diabetic Gastroparesis Treatment Market Regional and Country Analysis
8. Asia-Pacific Diabetic Gastroparesis Treatment Market
9. China Diabetic Gastroparesis Treatment Market
10. India Diabetic Gastroparesis Treatment Market
11. Japan Diabetic Gastroparesis Treatment Market
12. Australia Diabetic Gastroparesis Treatment Market
13. Indonesia Diabetic Gastroparesis Treatment Market
14. South Korea Diabetic Gastroparesis Treatment Market
15. Western Europe Diabetic Gastroparesis Treatment Market
16. UK Diabetic Gastroparesis Treatment Market
17. Germany Diabetic Gastroparesis Treatment Market
18. France Diabetic Gastroparesis Treatment Market
19. Italy Diabetic Gastroparesis Treatment Market
20. Spain Diabetic Gastroparesis Treatment Market
21. Eastern Europe Diabetic Gastroparesis Treatment Market
22. Russia Diabetic Gastroparesis Treatment Market
23. North America Diabetic Gastroparesis Treatment Market
24. USA Diabetic Gastroparesis Treatment Market
25. Canada Diabetic Gastroparesis Treatment Market
26. South America Diabetic Gastroparesis Treatment Market
27. Brazil Diabetic Gastroparesis Treatment Market
28. Middle East Diabetic Gastroparesis Treatment Market
29. Africa Diabetic Gastroparesis Treatment Market
30. Diabetic Gastroparesis Treatment Market Competitive Landscape and Company Profiles
31. Diabetic Gastroparesis Treatment Market Other Major and Innovative Companies
35. Diabetic Gastroparesis Treatment Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Diabetic Gastroparesis Treatment Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on diabetic gastroparesis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for diabetic gastroparesis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Treatment: Medication; Surgery
2) By Route Of Administration: Oral; Injectables
3) By Indication: Compensated Gastroparesis; Gastric Failure
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels
5) By End-user: Hospitals; Homecare; Specialty Clinics; Other End-users
Key Companies Mentioned: Cardinal Health Inc.; Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Ipca Laboratories Ltd.; Abbott Laboratories
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Cardinal Health Inc.
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd.
- Ipca Laboratories Ltd.
- Abbott Laboratories
- GlaxoSmithKline plc
- AstraZeneca plc
- Medtronics plc
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
- Kimberly-Clark Corporation
- Teva Pharmaceutical Industries Ltd.
- Janssen Global Services LLC
- Boston Scientific Corporation
- Fresenius Kabi AG
- Bausch Health Companies Inc.
- Allergan Inc.
- Salix Pharmaceuticals Inc.
- Ironwood Pharmaceuticals Inc.
- Wockhardt Ltd.
- ANI Pharmaceuticals Inc.
- Endologic LLC
- Vanda Pharmaceuticals Inc.
- Rhythm Pharmaceuticals Inc.
- Theravance Biopharma Inc.
- Neurogastrx Inc.
- Evoke Pharma Inc.
- CinRx Pharma LLC
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 3.86 Billion |
| Forecasted Market Value ( USD | $ 4.73 Billion |
| Compound Annual Growth Rate | 5.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 28 |
